+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

R

Actively Recruiting

Narcolepsy Type 2 NT2 is a lifelong condition causing excessive daytime sleepiness and difficulty staying awake, which can disrupt daily activities and quality of life. Researchers are studying TAK-360, a drug that acts like the brain chemical orexin, to evaluate its safety, tolerability, and potential to help adults with NT2 stay awake. This Phase 2 trial also aims to determine the right dosage of TAK-360. Participants will be randomly assigned to receive either TAK-360 tablets or matching placebo tablets orally for 4 weeks. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo during the treatment period. Throughout the study, participants will be monitored for treatment-emergent adverse events up to 15 weeks. Researchers will measure changes from baseline to week 4 in sleepiness using the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test. This helps evaluate how well TAK-360 helps participants stay awake and alert during the day.

Age: 18Years - 70YearsAll GendersPhase 2
52 locations